Critics have long questioned the effectiveness of Roche and GlaxoSmithKline's flu drugs, asking whether their benefits justify the estimated $2 billion spent to stockpile them for potential epidemics. Now, heading into flu season, scientists have an answer: No one knows.
In a move to ease antitrust concerns ahead of its multibillion-dollar asset swap with Novartis, GlaxoSmithKline announced in June that it would sell two of its mature meningitis jabs to Pfizer.
GlaxoSmithKline now has rights to develop inhaled therapeutics using Liquidia's PRINT particle engineering technology. The development builds on a drug delivery alliance between the two companies that commenced in 2012.
GlaxoSmithKline is pinning its hopes on consumer health, a unit whose margins it expects to see at 20% by 2020. But just how does it expect to get there?
Late last year GlaxoSmithKline set its sights on reorganizing and downsizing its R&D group, laying off hundreds of staffers in North Carolina as it concentrates research in the Philadelphia area and around Stevenage in the U.K. And now it's taking the ax to a satellite lab in France.
Just weeks after a group of castaways from the big GlaxoSmithKline reorg in North Carolina started their own biotech, Phoundry, focusing on establishing a pipeline of new peptide therapies, they've found a buyer for the company. Boston-based Intarcia says it is acquiring Phoundry with an eye to beefing up its work related to the ultra-extended-release diabetes therapy ITCA 650.
GlaxoSmithKline got a positive opinion from European regulators on its new treatment for severe asthma, setting the stage for a likely approval later this year.
GlaxoSmithKline has faced its fair share of scrutiny over a study of its antidepressant Paxil in teenagers, with some experts claiming that the company wrote off harmful side effects linked to the med. Now, a re-analysis of the original study shows that the trial trumpeted Paxil's benefits while downplaying serious side effects including suicide.
And the winner is … everyone. GlaxoSmithKline chose both of its incumbent agencies to continue handling media planning and buying for its newly consolidated GSK Consumer Healthcare business.
Georgetown's Dr. R. Scott Turner tested a therapeutic grade formulation of resveratrol in Alzheimer's patients, looking at two suspected biomarkers for the disease, the soluble proteins amyloid beta 42 and Abeta 40. Abeta 40 levels remained level among the group getting purified resveratrol, while the control group registered telltale declines as their dementia worsened.